Antibiotic Resistance and Overuse

by Food and Drug Administration (FDA)

The historical scourge known as the bubonic plague killed up to one-third of Europe's population in the 1300s. But in modern times, it has been controlled handily with the help of antibiotic drugs such as streptomycin, gentamicin and chloramphenical.

That is, until 1995, when a plague infection in a 16-year-old boy from Madagascar failed to respond to the usual antibiotic treatments. This first documented case of an antibiotic-resistant plague, reported in the September 1997 New England Journal of Medicine, eventually succumbed to another antibiotic.

In the United States and globally, many other infectious germs, including those that cause pneumonia, ear infections, acne, gonorrhea, urinary tract infections, meningitis, and tuberculosis, can now outwit some of the most commonly used antibiotics and their synthetic counterparts, antimicrobials. According to the Mayo Clinic in Rochester, Minn., drug resistance may have contributed to the 58 percent rise in infectious disease deaths among Americans between 1980 and 1992.

Antibiotic resistance isn't a new problem; resistant disease strains began emerging not long after the discovery of antibiotics more than 50 years ago. Penicillin and other antibiotics, which were initially viewed as miracle drugs for their ability to cure such serious and often life-threatening diseases as bacterial meningitis, typhoid fever, and rheumatic fever, soon were challenged by some defiant strains.

"What's different now," explains David Bell, M.D., an expert on antimicrobial resistance with the national Centers for Disease Control and Prevention, "is that we've reached a situation where it's no longer an isolated problem of this bug or that bug; virtually all important human pathogens treatable with antibiotics have developed some resistance."

Despite the frightening trend, most people aren't likely to encounter a "superbug" that can outsmart all antibiotics, says Mark Goldberger, M.D., director of the Food and Drug Administration's division of special pathogen and immunologic drug products. "For the average person walking around on the street, the risk at the moment remains low."

Still, as one antibiotic's effectiveness wanes, doctors are forced in many cases to rely on more expensive and toxic drugs. Resistance is "a big problem and growing," says Linda Tollefson, director of surveillance and compliance in FDA's Center for Veterinary Medicine. "You're dealing with living microbes that have shown an incredible ability to accommodate antibiotics and come out winning. We have no idea what they are going to do next. Our fear is that we're seeing the tip of the iceberg."

To stop infectious germs from gaining ground, experts the world over, including doctors and scientists from FDA, CDC, and the World Health Organization, have been focusing since 1995 on finding ways to prolong the lives of antibiotics and to encourage drug companies to develop new "miracle drugs."

Survival of the Fittest

Every time a patient takes penicillin or another antibiotic for a bacterial infection, the drug may kill most of the bacteria. But a few tenacious germs may survive by mutating or acquiring resistance genes from other bacteria. These surviving genes can multiply quickly, creating drug-resistant strains. The presence of these strains may mean that the patient's next infection will not respond to the first-choice antibiotic therapy. Also, the resistant bacteria may be transmitted to others in the patient's community.

Experts say the risk is greatest, but still not high, for those in hospitals, nursing homes, and other settings where people tend to be sick often. In these environments, people may be taking an array of antibiotics (one researcher estimates that 25 to 40 percent of hospital patients get intravenous antibiotics), increasing the chance of a resistant germ originating within their own bodies. Also, hospitalized patients are surrounded by others whose infectious diseases may spread, and their immune systems may be weakened and incapable of beating the infectious bugs.

Organisms that have already developed defenses against antibiotic attack include:

Staphylococcus aureus. This bacterium, which is the biggest cause of infections in patients in U.S. hospitals, can infect burns, skin, and surgical wounds. Since 1996, at least four patients — three in the United States and one in Japan — reportedly were infected with a strain that was partially resistant to normal doses of the powerful, last-resort antibiotic vancomycin. Some strains of S. aureus have already shown resistance to all antibiotics other than vancomycin, raising the fear that an invincible strain is near at hand.

Enterococcus. This organism can cause everything from urinary tract to heart valve infections. Some strains can outmatch many previously effective antibiotics.

Streptococcus pneumoniae. Up to 30 percent of the strains of this bacterium, which can cause pneumonia, meningitis, and ear infections, are at least partially resistant to antibiotics in the penicillin family, according to the Mayo Clinic.

Other germs that have grown resistant to formerly reliable antibiotics include Neisseria gonorrhoeae, the cause of the sexually transmitted disease gonorrhea; the food poisoners Salmonella, Escherichia coli (E. coli) and other Enterobacteriaceae; and Mycobacterium tuberculosis, which causes TB. Data from Finland shown in the chart above (source: Centers for Disease Control and Prevention CAUSE newsletter, October 1997) suggest that as fewer doses (measured in units called "defined daily doses" per 1,000 inhabitants per day) of the antibiotic erythromycin were taken to treat group A streptococci, a decrease in resistance followed several years later.

Luckily, Goldberger says, there is a renewed interest among U.S. drug companies in developing new antibiotics to target organisms that are developing resistance. Earlier this year, an FDA advisory panel recommended approval for the antibiotic Synercid. If approved, it could be used to treat such hospital-acquired infections as pneumonia and some vancomycin-resistant infections of the bloodstream.

About the Author

www.fda.gov
FDA is A United States government body that oversees medical devices, including contact lenses, intraocular lenses, excimer lasers and eyedrops. In the US, these products must be approved by the FDA before they can be marketed.